Mapping Real-World Rheumatoid Arthritis Patients to Clinical Trial Eligibility Criteria

被引：0
|
作者：
Keystone, Edward [1 ]
Olszynski, Wojciech [2 ]
Bessette, Louis [3 ]
Rahman, Proton [4 ]
Rampakakis, Emmanouil [5 ]
Lehman, Allen [6 ]
Asin-Milan, Odalis [6 ]
Nantel, Francois [6 ]
Rachich, Meagan [6 ]
机构：
[1] Univ Toronto, Mt Sinai Hosp, Toronto, ON, Canada
[2] Univ Saskatchewan, Saskatoon, SK, Canada
[3] Laval Univ, Quebec City, PQ, Canada
[4] Mem Univ, St John, NF, Canada
[5] JSS Med Res Inc, Montreal, PQ, Canada
[6] Janssen Inc, Toronto, ON, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2020年 / 47卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
178
引用
收藏
页码：1107 / 1108
页数：2
相关论文
共 50 条
  • [21] Impact of broadening clinical trial eligibility criteria for advanced non small cell lung cancer patients: Real-world analysis.
    Harvey, R. Donald
    Rubinstein, Wendy S.
    Ison, Gwynn
    Khozin, Sean
    Chen, Li
    Miller, Robert S.
    Jun, Monika
    Stepanski, Edward
    Hyde, Brigham
    Uldrick, Thomas S.
    Komatsoulis, George Anthony
    Roberts, Jeremy
    Garrett-Mayer, Elizabeth
    Schilsky, Richard L.
    Schenkel, Caroline
    Kim, Edward S.
    Bruinooge, Suanna S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [22] Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
    Al-Baimani, K.
    Jonker, H.
    Zhang, T.
    Goss, G. D.
    Laurie, S. A.
    Nicholas, G.
    Wheatley-Price, P.
    CURRENT ONCOLOGY, 2018, 25 (04) : E291 - E297
  • [23] Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real-world setting in Taiwan
    Chen, Kun-Hung
    Li, Ko-Jen
    Fang, Yao-Fan
    Hsieh, Song-Chou
    Chen, Ying-Chou
    Lee, Chyou-Shen
    Luo, Shue-Fen
    Cheng, Tien-Tsai
    Tsai, Wen Chan
    Lo, Yu-Chen
    Lan, Joung-Liang
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (07)
  • [24] Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting
    Atsumi, Tatsuya
    Fujio, Keishi
    Yamaoka, Kunihiro
    Tomobe, Minako
    Kuroyanagi, Kazuyuki
    Kameda, Hideto
    MODERN RHEUMATOLOGY, 2018, 28 (05) : 780 - 788
  • [25] Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real World Population of Advanced Lung Cancer Patients?
    Al-Baimani, Khalid
    Jonker, Hannah
    Zhang, Tinghua
    Goss, Glenwood
    Laurie, Scott A.
    Nicholas, Garth
    Wheatley-Price, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S368 - S369
  • [26] Real-world retention rates of biologics in patients with rheumatoid arthritis
    Takami, Kenji
    Tsuji, Shigeyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [27] Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis
    Knapp, Keith
    Mueller, Eric
    Craig, Gary
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [28] REAL-WORLD EFFECTIVENESS OF FILGOTINIB IN BELGIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Diederik, D. C.
    Durez, P.
    Lenaerts, J.
    Westhovens, R.
    Verschueren, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1401 - 1401
  • [29] Tailoring biologic therapy for real-world rheumatoid arthritis patients
    Romano, Ciro
    Esposito, Sergio
    Ferrara, Roberta
    Cuomo, Giovanna
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (05) : 661 - 674
  • [30] Real-world retention rates of biologics in patients with rheumatoid arthritis
    Kenji Takami
    Shigeyoshi Tsuji
    Scientific Reports, 13
12345